Form 4: Agenus CEO Garo Armen Receives Stock in Lieu of Cash Salary

Agenus CEO Garo Armen received 5,347 shares of common stock as part of his salary for the pay period ending December 13, 2024.

Summary

• Garo H. Armen, CEO of Agenus Inc., received 5,347 shares of common stock as part of his salary for the pay period ending December 13, 2024.
• The stock was issued in lieu of cash payment, as approved by the Agenus Inc. Compensation Committee.
• The shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive and are fully vested upon issuance.
• The price of the stock was $3.05 per share, which was the closing price on December 13, 2024.
• Mr. Armen also indirectly owns 118,440 shares through IRA accounts and a trust, and has a partial pecuniary interest in 5,000 shares held by Pixie Partners.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally neutral to positive. The use of stock instead of cash can be seen as a positive sign of management's confidence in the company's future.

Positives

• The use of stock in lieu of cash for executive compensation can align management interests with shareholder value.
• The shares are fully vested upon issuance, indicating immediate ownership and alignment with company performance.

Management Comments

• Garo H. Armen's salary is being paid in stock, in lieu of cash, at his request and with the approval of the Agenus Inc. Compensation Committee.

Industry Context

The use of stock-based compensation is a common practice in the biotechnology industry to conserve cash and align executive interests with shareholder value. This is a standard practice for many companies, especially those in the growth phase.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotech industry, often used by companies like Agenus to conserve cash and align executive interests with shareholder value.
• Many biotech companies, such as Moderna and BioNTech, use stock options and grants as part of their executive compensation packages.
• The vesting schedule of these grants can vary, but immediate vesting, as seen in this case, is not uncommon for salary-related stock grants.

Stakeholder Impact

• Shareholders may view the stock-based compensation positively as it aligns management interests with company performance.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates

Keywords

Agenus, Garo Armen, stock compensation, equity incentive, executive compensation, insider trading, beneficial ownership